Table 1.
Recommended first-line and second-line antimicrobials in the treatment of MRMP in children, optimal doses, and duration of use
| Country | Line | Drug | Route of administration | Dose (mg/kg/day) | Duration of treatment (day) | Notice |
|---|---|---|---|---|---|---|
| Japan [19,21] | First-line | Erythromycin | Oral | 25–50 | 14 | |
| Clarithromycin | Oral | 10–15 | 10 | |||
| Azithromycin | Oral | 10 | 3 | |||
| Second-line | Tosufloxacin | Oral | 12 | 7–14 | ≤8 years of age | |
| Minocycline | Oral of IV | 2–4 | 7–14 | |||
| Hong Kong [20] | Second-line | Doxycycline | Oral | 4 | Not mentioned | >8 years of age |
| Levofloxacin | Oral | 8 | Not mentioned | ≤8 years of age | ||
| Minocycline | IV | 4 | Not mentioned | When not tolerable oral medicine | ||
| USA [1] | First-line | Azithromycin | Oral | 10 on day 1, and followed by 5 on days 2–5 | 5 | |
| Oral | 15 | Not mentioned | ||||
| Clarithromycin | Oral | 40 | Not mentioned | |||
| Erythromycin | IV | 10 on days 1–2 | Not mentioned | |||
| Azithromycin | IV | 20 | Not mentioned | |||
| Erythromycin lactobionate | Oral | 24 | Not mentioned | >7 years of age | ||
| Second-line | Doxycycline | Oral | 500 mg/day | Not mentioned | Adolescents | |
| Levofloxacin | IV | 16–20 | Not mentioned | Adolescents | ||
| Moxifloxacin | Oral | 400 mg/day | Not mentioned | Adolescents |
MRMP, macrolide-resistant Mycoplasma pneumoniae pneumonia; IV, intravenous.